Clinical and pharmacological group: & nbsp

Antifungal means

Included in the formulation
  • Gino-Pevaril®
    suppositories the vagina. 
  • Ifenek
    solution externally 
    Italfarmaco SpA     Italy
  • Ifenek
    powder externally 
    Italfarmaco SpA     Italy
  • Ifenek
    suppositories the vagina. 
    Italfarmaco SpA     Italy
  • Ifenek
    cream externally 
    Italfarmaco SpA     Italy
  • Ecodax®
    cream externally 
  • АТХ:

    G.01.A.F.05   Econazole

    Pharmacodynamics:

    Antifungal for local and external use. Is an imidazole derivative. Has a wide range of antifungal action. Active with respect to Trichophyton rubrum, Trichophyton tonsurans, Microsporum canis, Epidermophyton floccosum, Candida albicans and some Gram-positive bacteria.

    Pharmacokinetics:

    When applied to the skin, systemic absorption is minimal and practically insignificant. Therapeutic concentrations are created in the epidermis (including the stratum corneum), as well as in the dermis. Less than 1% of the applied dose is excreted with feces and kidneys.

    Indications:

    For topical application: vulvovaginal mycoses, fungal balanitis; mycosis of the auditory canal.

    For external use: fungal lesions of the skin, hair; erythrasma.

    VIII.H60-H62.H62.2 *   External otitis with fungal infections

    I.B35-B49.B35.4   Mycosis of the trunk

    I.B35-B49.B35.3   Mycosis of the feet

    I.B35-B49.B35.2   Mycosis brushes

    I.B35-B49.B35.0   Mycosis of the beard and head

    I.B35-B49.B37.4   Candidiasis of other urogenital localizations

    I.B35-B49.B37.3   Candidiasis of the vulva and vagina (N77.1 *)

    I.B35-B49.B37.2   Candidiasis of skin and nails

    XII.L00-L08.L08.1   Erythrasm

    XII.L20-L30.L30.5   Pitiriasis white

    XIV.N70-N77.N76   Other inflammatory diseases of the vagina and vulva

    XIV.N70-N77.N77.1 *   Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere

    Contraindications:

    Hypersensitivity to econazole.

    Carefully:

    Pregnancy and lactation.

    Pregnancy and lactation:

    Recommendations for FDA category B (intravaginal application) and FROM (topical application). Econazole nitrate should be used during pregnancy only when the intended benefit to the mother exceeds the potential risk to the fetus (adequate and strictly controlled studies in humans have not been performed).

    It is not known whether econazole nitrate is excreted into breast milk of women. For the period of treatment of econazole with nitrate, the issue of stopping breastfeeding should be addressed.

    Dosing and Administration:

    Cream and powder are applied to the affected areas of the skin and slightly rubbed: with mycosis of the feet, hands and trunk - once a day, with colored lichen - 2 times a day (morning and evening). To prevent the recurrence of mycosis of the feet after the elimination of clinical manifestations, the treatment is continued for another 2 weeks.

    The solution is prepared immediately before use, 10 cm3 (1 dose) is diluted in warm water in a ratio of 1: 1 and the external genitalia is washed 1-2 times a day for 3-5 days.

    The vaginal suppository is injected deep into the vagina in the prone position just before bedtime for 3 days. If the effectiveness is insufficient, it is possible to extend the course to 6 days and repeat the course after 10 days.

    Onychomycosis. Outwardly. Apply once a day under an occlusive dressing.

    Side effects:

    With topical application: burning, redness, possible urticaria rash.

    For external use: possible development of irritation, burning, itching, erythema, dryness, hypopigmentation, skin atrophy.

    Overdose:

    There are no data on the overdosage of econazole nitrate in humans.

    Interaction:

    There is a possibility of competitive interaction of econazole with acenocoumarol and / or warfarin (substrate CYP3A4 / 2C29). However, taking into account that econazole when topical application is poorly absorbed into the systemic circulation, the emergence of clinically significant interactions is unlikely. Patients receiving econazole and acenocoumarol or warfarin, should be careful and monitor the parameters of blood clotting.

    Special instructions:

    Avoid contact with econazole in the eyes.

    To prevent the recurrence of candidiasis and dermatomycosis of the legs and trunk treatment is required for at least 2 weeks, and for dermatophyte stops - at least 1 month; if there is no effect, the therapy should be stopped and the diagnosis reviewed. In the case of insufficient effectiveness of the standard 3-day course for vaginal candidiasis, it may be continued for 3 days and a repeat course in 10 days. If there is no effect in the indicated periods of therapy, treatment should be stopped and the diagnosis clarified.

    When the first symptoms appear, indicating increased sensitivity or irritation, econazole nitrate must be discarded.

    During menstrual bleeding, the drug is administered intravaginally according to the usual schedule.

    When vulvovaginal mycoses necessarily treatment and sexual partner.

    Instructions
    Up